# Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

> **NCT05989126** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Diabetic Macular Edema (DME)
- Neovascular Age-Related Macular Degeneration (nAMD)

## Interventions

- **DRUG:** aflibercept 8 mg PFS

## Key facts

- **NCT ID:** NCT05989126
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-15
- **Primary completion:** 2024-05-31
- **Final completion:** 2024-05-31
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989126

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989126, "Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05989126. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*